Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 6/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29440728 | 0.81 | TDP1 (0.52) | TDP1SMN1; SMN2KDM4EMAPTL3MBTL1 | |
| SCHEMBL539611 | 0.81 | TDP1 (0.52) | TDP1SMN1; SMN2KDM4EMAPTL3MBTL1 | |
| SCHEMBL7015500 | 0.81 | TDP1 (0.48) | TDP1L3MBTL1HTR2AHTR2CHTR2B | |
| SCHEMBL27875406 | 0.78 | CYP1A2 (0.42) | TDP1SMN1; SMN2KDM4EMAPTL3MBTL1 | |
| SCHEMBL27331521 | 0.78 | TDP1 (0.48) | TDP1SMN1; SMN2KDM4EMAPTL3MBTL1 | |
| SCHEMBL31329852 | 0.78 | CYP1A2 (0.42) | TDP1SMN1; SMN2KDM4EMAPTL3MBTL1 | |
| SCHEMBL9455835 | 0.78 | MAPT (0.41) | TDP1SMN1; SMN2KDM4EMAPTL3MBTL1 | |
| SCHEMBL8781407 | 0.76 | TSHR (0.41) | TDP1SMN1; SMN2KDM4EMAPTL3MBTL1 | |
| SCHEMBL10668912 | 0.75 | ALDH1A1 (0.41) | TDP1SMN1; SMN2KDM4EMAPTL3MBTL1 | |
| SCHEMBL712542 | 0.75 | MAPT (0.39) | TDP1SMN1; SMN2KDM4EMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388541-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4511117-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2023205465-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| CN-102333781-B | Tricyclic pyrazolopyrimidine derivatives | DAIICHI SANKYO CO LTD | 2014-06-11 | — | — | CN | disclosed |
| US-8445504-B2 | Tricyclic pyrazolopyrimidine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-05-21 | — | — | US | disclosed |
| US-20120202833-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-09 | — | — | US | disclosed |
| US-8236813-B2 | Tricyclic pyrazolopyrimidine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-07 | — | — | US | disclosed |
| EP-2402349-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-01-04 | — | — | EP | disclosed |
| US-20110071170-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202833-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | HSP90AB1, HSP90B1, HSP90AA1 | TDP1 690/4885SMN1; SMN2 4213/4885KDM4E 3698/4885 |
| US-20250388541-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | SCN1B, CLIC1, HCN1 | TDP1 3016/4885SMN1; SMN2 760/4885KDM4E 4567/4885 |
| US-20110071170-A1 | TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVES | HSP90AB1, HSP90B1, HSP90AA1 | TDP1 690/4885SMN1; SMN2 4213/4885KDM4E 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.